Oppenheimer analyst Jay Olson assumed coverage of Praxis Precision (PRAX) with an Outperform rating and $97 price target following quarterly results. Given the multiple upcoming readouts across its pipeline, the firm remains encouraged by management’s execution. For the vomatrigine program, Oppenheimer looks forward to the RADIANT and POWER1 registrational Phase 2/3 topline results, still expected in mid-2025 and the second half of 2025, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- AMD upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls
- Praxis Precision initiated with a Buy at Chardan
- Praxis Precision Medicines: Advancements and Financial Outlook
- Praxis Precision price target raised to $76 from $73 at Baird
- Praxis Precision hosted investor event on clinical programs